ArticleCell2020
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04751682 (A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenovirus Vector COVID-19 Vaccine), which is not on this map. Cited by 411 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
411citing papers in PubMed, 1 pooled it
11.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenovirus Vector COVID-19 Vaccine (BBV154) in Healthy Volunteers
Who cites it
411 citing papers in PubMed, 1 synthesis or guideline pooled it, 620 citations in OpenAlex.
- Mucosal immunity and vaccine development.Signal transduction and targeted therapy · 2026Pooled it
- Mucosal immunization with an adenoviral vector expressing a prefusogenic F protein protects the upper and lower respiratory tracts of cotton rats against live respiratory syncytial virus challenge.Human vaccines & immunotherapeutics · 2026Article
- Review
- Spatiotemporal heterologous vaccination relies on type I interferons at priming to enhance mucosal immunity.EMBO molecular medicine · 2026Article
- Human lungs maintain tissue-resident memory T cells against a broad spectrum of pathogens.Nature immunology · 2026Article
- The Role of Human Viral Entry Receptor Mouse Models in Advancing Antiviral Antibodies and Vaccines.Vaccines · 2026Review
- Harnessing mucosal immunity for protective vaccines.Nature reviews. Immunology · 2026Review
- Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid.PLoS pathogens · 2026Article
- CD8MedComm · 2026Review
- A Multiepitope Intranasal Adenoviral Vaccine Induces Robust Mucosal Immunity and Protection against SARS‑CoV‑2.Journal of nanobiotechnology · 2026Article
- Intranasal boosting induces variant-specific responses in SARS-CoV-2 vaccine-imprinted mice.Nature communications · 2026Article
- A subunit vaccine for multiple respiratory viruses.Science advances · 2026Article
- B cell αv integrin regulates tissue specialization and clonal expansion of lung germinal center and memory B cells after viral infection.Science advances · 2026Article
- Article
- Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant.Nature biomedical engineering · 2026Article
- Effects of cellular receptors on the vaccine efficacies of adenovirus vector-based vaccines following intramuscular and intranasal administration.Scientific reports · 2026Article
- Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.iScience · 2026Article
- Accumulation of mutations in nsp4, E, and the S2 subunit underlies mammalian cell tropism expansion and virulence attenuation of avian coronavirus.PLoS pathogens · 2026Article
- Construction of the Multi-Epitope HFMD Vaccine Based on an Attenuated CVB3 Vector and Evaluation of Immunological Responses in Mice.Vaccines · 2026Article
- Combination of adenovirus vector and subunit protein elicits a robust immune response against the SARS-CoV-2 Omicron variant.Molecular biomedicine · 2026Article
351 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 3 institutions in 1 country.
Ahmed O HassanDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Natasha M KafaiDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Igor P DmitrievDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Julie M FoxDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Brittany K SmithDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Ian B HarveyDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Rita E ChenDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Emma S WinklerDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Alex W WesselDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
James Brett CaseDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Elena KashentsevaDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Broc T McCuneDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Adam L BaileyDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Haiyan ZhaoDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Laura A VanBlarganDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Ya-Nan DaiDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Meisheng MaDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Lucas J AdamsDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Swathi ShrihariDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Jonathan E DanisDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Lisa E GralinskiDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Yixuan J HouDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Arthur S KimDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Shamus P KeelerDivision of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Daniela WeiskopfCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Michael J HoltzmanDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Daved H FremontDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA.
David T CurielDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: dcuriel@wustl.edu.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: diamond@wusm.wustl.edu.
Washington University in St. Louis · USUniversity of North Carolina at Chapel Hill · USLa Jolla Institute for Immunology · US
Funding
NATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8MTRAINING PROGRAM IN IMMUNOLOGY AND IMMUNOGENETICST32AI007163 · NIAID · WASHINGTON UNIVERSITY · PI Kenneth M Murphy, Kodi S Ravichandran · 1985 to 2026
$14.8MCOVID Supplement B Cell Epitope Discovery and Mechanisms of Antibody Protection.75N93019C00062 · NIAID · WASHINGTON UNIVERSITY · PI FREMONT, DAVED · 2019 to 2023
$11.7MDefining and Controlling Airway DiseaseR35HL145242 · NHLBI · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2019 to 2025
$6.6MRespiratory Virus Vaccine and Adjuvant Exploration - Equipment SupplementU01AI149644 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S · 2019 to 2023
$6.1MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MHuman neutralizing antibodies for Zika virusR01AI127828 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E, DIAMOND, MICHAEL S · 2017 to 2021
$3.9MPARP9-DTX3L Control Of Viral Infection and Airway DiseaseR01AI130591 · NIAID · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2017 to 2021
$3.0MAnalysis of factors controlling coxsackievirus population dynamics in the intestineF32AI138392 · NIAID · WASHINGTON UNIVERSITY · PI MCCUNE, BROC TAYLOR · 2018 to 2020
$126kRegulation of Antiviral Responses in Plasmacytoid Dendritic Cells to Chikungunya Virus by the Gut MicrobiotaF30AI152327 · NIAID · WASHINGTON UNIVERSITY · PI WINKLER, EMMA SUENING · 2021 to 2022
$84kNHLBI NIH HHS R35 HL145242NIAID NIH HHS 75N93019C00062NIAID NIH HHS F30 AI152327NIAID NIH HHS F32 AI138392NIAID NIH HHS HHSN272201200026CNIAID NIH HHS HHSN272201400018CNIAID NIH HHS R01 AI127828NIAID NIH HHS R01 AI130591NIAID NIH HHS R01 AI157155NIAID NIH HHS T32 AI007163NIAID NIH HHS U01 AI149644NIGMS NIH HHS T32 GM007200
Abstract
The coronavirus disease 2019 pandemic has made deployment of an effective vaccine a global health priority. We evaluated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a prefusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor. Intramuscular dosing of ChAd-SARS-CoV-2-S induces robust systemic humoral and cell-mediated immune responses and protects against lung infection, inflammation, and pathology but does not confer sterilizing immunity, as evidenced by detection of viral RNA and induction of anti-nucleoprotein antibodies after SARS-CoV-2 challenge. In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels of neutralizing antibodies, promotes systemic and mucosal immunoglobulin A (IgA) and T cell responses, and almost entirely prevents SARS-CoV-2 infection in both the upper and lower respiratory tracts. Intranasal administration of ChAd-SARS-CoV-2-S is a candidate for preventing SARS-CoV-2 infection and transmission and curtailing pandemic spread.
Indexed as
Immunogenicity, VaccineAdenoviridaeAdministration, IntranasalAnimalsAntibodies, NeutralizingAntibodies, ViralChlorocebus aethiopsCoronavirus InfectionsCOVID-19COVID-19 VaccinesFemaleHEK293 CellsHumansInjections, IntramuscularMiceMice, Inbred BALB CAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike glycoprotein, SARS-CoVViral VaccinesantibodyCOVID-19IgAintranasalmucosal immunitypathogenesisprotectionSARS-CoV-2T cellsvaccine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04751682ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.